Cost-benefit analysis of new cancer medicines: The difficult choices of governments

Share :
Published: 8 Oct 2023
Views: 102
Rating:
Save
Dr Nwamaka Lasebikan, Prof P.G. Roy, Dr Didier Verhoeven

To help improve the quality of breast cancer care globally, a collaboration of leading partners has created the Grand Rounds in Breast Cancer series of educational webinars. This session with ecancer enables learners the opportunity to discuss controversies, real-life challenges and effective application of existing knowledge.

Dr Nwamaka Lasebikan (University of Nigeria Teaching Hospital, Enugu, Nigeria) presents her talk on 'Cost-benefit analysis of new cancer medicines: The difficult choices of governments' where she details the difficulties faced by LMIC healthcare systems and how cost-benefit analysis is needed to ensure equitable access to care for populations.

Prof P.G. Roy (University of Oxford, Oxford, UK) and Dr Didier Verhoeven (University of Antwerp, Antwerp, Belgium) then pose questions to Dr Lasebikan including on how to calculate this cost-benefit analysis and on the Choosing Wisely initiative.